Literature DB >> 33605411

Integrated bioinformatics analysis identified MTHFD1L as a potential biomarker and correlated with immune infiltrates in hepatocellular carcinoma.

Junhui Chen1, Jie Yang1, Qingchun Xu1, Zhenyu Wang1, Jun Wu1, Liukui Pan1, Kai Huang1, Chen Wang1.   

Abstract

Liver hepatocellular carcinoma (LIHC) is one of the most frequently occurring primary malignant liver tumors and seriously harms people's health in the world. Methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L) has been shown to be associated with colon cancer cell proliferation, colony formation and invasion. In the present study, a total of 370 LIHC and 51 normal samples data were downloaded from The Cancer Genome Atlas (TCGA) database. Bioinformatics and immunohistochemistry (IHC) analysis showed that MTHFD1L is highly expressed in liver tumors. Correlation analysis suggested the differences of vital status between high- and low-expression MTHFD1L groups of LIHC. Univariate and multivariate Cox proportional hazards regression were performed to identify the relationship between clinical characteristics and overall survival (OS). In addition, to explore whether MTHFD1L has an effect on the immune infiltration of LIHC. The correlation between MTHFD1L expression and 24 immune cells were analyzed by ImmuneCellAI database. Furthermore, we combined three databases CIBERSORT, TIMER and ImmuneCellAI to do a comprehensive validation and determined that dendritic cells (DCs) resting, macrophage M0 and macrophage M2 closely related to the expression of MTHFD1L. The results showed that MTHFD1L was a potential prognostic biomarker for LIHC, and could help to elucidate that how the immune microenvironment promotes liver cancer development.
© 2021 The Author(s).

Entities:  

Keywords:  MTHFD1L; hepatocellular carcinoma; immune cell; prognosis; tumor microenvironment

Mesh:

Substances:

Year:  2021        PMID: 33605411      PMCID: PMC7897918          DOI: 10.1042/BSR20202063

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  46 in total

Review 1.  Rheostatic Functions of Mast Cells in the Control of Innate and Adaptive Immune Responses.

Authors:  Barbara Frossi; Francesca Mion; Claudio Tripodo; Mario P Colombo; Carlo E Pucillo
Journal:  Trends Immunol       Date:  2017-04-25       Impact factor: 16.687

2.  Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells.

Authors:  John J Engelhardt; Bijan Boldajipour; Peter Beemiller; Priya Pandurangi; Caitlin Sorensen; Zena Werb; Mikala Egeblad; Matthew F Krummel
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

3.  Is the outcome after hepatectomy for transitional hepatocholangiocarcinoma different from that of hepatocellular carcinoma and mass-forming cholangiocarcinoma? A case-matched analysis.

Authors:  Damiano Gentile; Matteo Donadon; Luca Di Tommaso; Laura Samà; Eloisa Franchi; Guido Costa; Ana Lleo; Guido Torzilli
Journal:  Updates Surg       Date:  2020-05-22

Review 4.  Circular RNAs in hepatocellular carcinoma: Biomarkers, functions and mechanisms.

Authors:  Lipeng Qiu; Han Xu; Mengchen Ji; Dongsheng Shang; Ziwen Lu; Yihang Wu; Zhigang Tu; Hanqing Liu
Journal:  Life Sci       Date:  2019-07-15       Impact factor: 5.037

5.  Prognostic profiling of the immune cell microenvironment in Ewing´s Sarcoma Family of Tumors.

Authors:  David Stahl; Andrew J Gentles; Ralf Thiele; Ines Gütgemann
Journal:  Oncoimmunology       Date:  2019-10-13       Impact factor: 8.110

6.  Profiles of immune cell infiltration and their clinical significance in head and neck squamous cell carcinoma.

Authors:  Yu Jin; Xing Qin
Journal:  Int Immunopharmacol       Date:  2020-03-04       Impact factor: 4.932

Review 7.  World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma.

Authors:  Catherine de Martel; Delphine Maucort-Boulch; Martyn Plummer; Silvia Franceschi
Journal:  Hepatology       Date:  2015-10       Impact factor: 17.425

8.  Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer.

Authors:  Marie-Lisa Eich; Maria Del Carmen Rodriguez Pena; Darshan Shimoga Chandrashekar; Alcides Chaux; Sumit Agarwal; Jennifer B Gordetsky; James E Ferguson; Guru P Sonpavde; George J Netto; Sooryanarayana Varambally
Journal:  Transl Oncol       Date:  2019-08-08       Impact factor: 4.243

9.  Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry.

Authors:  Le Ying; Feng Yan; Qiaohong Meng; Xiangliang Yuan; Liang Yu; Bryan R G Williams; David W Chan; Liyun Shi; Yugang Tu; Peihua Ni; Xuefeng Wang; Dakang Xu; Yiqun Hu
Journal:  J Transl Med       Date:  2017-10-12       Impact factor: 5.531

10.  Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment.

Authors:  Wen-Hao Xu; Yue Xu; Jun Wang; Fang-Ning Wan; Hong-Kai Wang; Da-Long Cao; Guo-Hai Shi; Yuan-Yuan Qu; Hai-Liang Zhang; Ding-Wei Ye
Journal:  Aging (Albany NY)       Date:  2019-09-07       Impact factor: 5.682

View more
  3 in total

1.  Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer.

Authors:  Nuzhat Sial; Saba Saeed; Mukhtiar Ahmad; Yasir Hameed; Abdul Rehman; Mustansar Abbas; Rizwan Asif; Hamad Ahmed; Muhammad Safdar Hussain; Jalil Ur Rehman; Muhammad Atif; Muhammad Rashid Khan
Journal:  Int J Gen Med       Date:  2021-10-21

2.  Clinical Value for Diagnosis and Prognosis of Signal Sequence Receptor 1 (SSR1) and Its Potential Mechanism in Hepatocellular Carcinoma: A Comprehensive Study Based on High-Throughput Data Analysis.

Authors:  Liang Chen; Yunhua Lin; Guoqing Liu; Rubin Xu; Yiming Hu; Jiaheng Xie; Hongzhu Yu
Journal:  Int J Gen Med       Date:  2021-10-30

3.  Estrogen Receptor-α Suppresses Liver Carcinogenesis and Establishes Sex-Specific Gene Expression.

Authors:  Mara H O'Brien; Henry C Pitot; Sang-Hyuk Chung; Paul F Lambert; Norman R Drinkwater; Andrea Bilger
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.